Evidence map›Paper›PMID 22715212›Full record

ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2012

HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms.

Lynn E Taylor, Tracy Swan, Kenneth H Mayer

Open access · bronzeAbstract readReview
In one paragraph

Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 3 pooled it
9.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 3 syntheses or guidelines pooled it, 149 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Observational
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Lynn E TaylorDepartment of Medicine, Brown University, Providence, RI 02906, USA. LTaylor@Lifespan.org
Tracy Swan
Kenneth H Mayer
Brown University · USHarvard University · USTreatment Action Group · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Daniel Lingwood · 2004 to 2026
$94.4M
Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI JOSEPH W HOGAN · 1998 to 2026
$51.7M
Nutrition and Metabolism CoreP30DA013868 · NIDA · TUFTS UNIVERSITY BOSTON · PI TANG, ALICE M · 2002 to 2012
$10.0M
Buprenorphine as a Bridge to HCV Treatment for HIV/HCV Coinfected Opioid UsersK23DA020383 · NIDA · MIRIAM HOSPITAL · PI TAYLOR, LYNN ERICA · 2008 to 2012
$882k
NIAID NIH HHS P30 AI042853NIAID NIH HHS P30 AI060354NIAID NIH HHS P30 AI42853NIAID NIH HHS P30 AI60354NIDA NIH HHS K23 DA020383NIDA NIH HHS K23DA020383-01NIDA NIH HHS P30 DA013868
6 · The paper itself

Abstract

Chronic hepatitis C virus (HCV) infection has become a major threat to the survival of human immunodeficiency virus (HIV)-infected persons in areas where antiretroviral therapy is available. In coinfection, viral eradication has been difficult to attain, and HCV therapy is underused. Novel therapies may be particularly beneficial for this population, yet studies lag behind those for HCV monoinfection. Increasingly, incident HCV among HIV-infected men who have sex with men is associated with sexual risk behavior further research should be performed to refine understanding of the causal mechanism of this association. The phenomenon of aggressive hepatic fibrogenesis when HIV infection precedes HCV acquisition requires longer-term observation to ensure optimal timing of HCV therapy. Medical management in coinfection will be improved by enhancing HCV detection, with annual serologic testing, screening with HCV RNA to detect acute infection, and HIV testing of HCV-infected individuals; by addressing HCV earlier in coinfected persons; and by universal consideration for HCV therapy. HCV drug trials in individuals coinfected with HIV should be expedited. HIV/HCV coinfection remains a growing and evolving epidemic; new developments in therapeutics and improved care models offer promise.

Indexed as

CoinfectionAntiviral AgentsDisease ProgressionHepacivirusHepatitis C, ChronicHIVHIV InfectionsHumansIncidenceLiver CirrhosisMass ScreeningProlineRisk-TakingRNA, ViralSexual BehaviorAntiviral AgentsN-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamideProlineRNA, Viral

Identifiers

PMID22715212
PMCPMC3491862
OpenAlexW2098521993

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.